폐암 (NSCLC)

30개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved30 programs
AntibodyCurated CoreFDABristol Myers SquibbApproved

nivolumab (Opdivo, BMS-936558)

Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1280Status Approved
AntibodyCurated CoreFDAAmgenApproved

tarlatamab (Imdelltra, AMG 757, tarlatamab-dlle)

Extensive-stage small cell lung cancer after platinum-based chemotherapy · DLL3 × CD3

#DLL3CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 39Status Approved
ADCCurated CoreFDAstaleGenmabApproved

Tisotumab Vedotin (Tisotumab Vedotin)

Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung · Solid Malignancies

#SolidMalignancies#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 14Status Approved
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab plus nivolumab)

Melanoma; Non Small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#monoclonal-antibody#NonSmallCellLungCancer+1
Trials 32Status Recruiting
AntibodyLimited DatastaleMerck Sharp & Dohme LLCPhase 3

H1 receptor antagonist (H1 receptor antagonist)

Ovarian Cancer; Fallopian Tube Cancer · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase3#monoclonal-antibody#OvarianCancer+3
Trials 31Status Recruiting
AntibodyLimited DatastaleMerck Sharp & Dohme LLCPhase 3

H2 receptor antagonist (H2 receptor antagonist)

Ovarian Cancer; Fallopian Tube Cancer · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase3#monoclonal-antibody#OvarianCancer+2
Trials 31Status Recruiting
AntibodyLimited DatastalePfizerPhase 1

sasanlimab (sasanlimab)

Carcinoma, Pancreatic Ductal; Colorectal Neoplasms · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase1#monoclonal-antibody#Carcinoma+3
Trials 23Status Discontinued
AntibodyLimited DatastaleJanssen Research & Development,…Phase 2

Cetrelimab (Cetrelimab)

Carcinoma, Non-Small-Cell Lung · Neoplasms

#Neoplasms#Antibody#Phase2#monoclonal-antibody#Carcinoma+2
Trials 20Status Recruiting
AntibodyLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Vibostolimab (Vibostolimab)

Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#monoclonal-antibody#NeoplasmMetastasis+1
Trials 19Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 1

durvalumab (Imfinzi, Administration of ceralasertib and durvalumab)

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer · Adv Solid Malig - H&N SCC, ATM Pro / Def

#AdvSolidMalig-HNSCCATMProDef#Antibody#Phase1#monoclonal-antibody#AdvSolidMalig-HNSCC+3
Trials 12Status Recruiting
ADCStandard DatabasestaleSeagen Inc.Phase 2

ladiratuzumab vedotin (ladiratuzumab vedotin)

Small Cell Lung Cancer; Non-small Cell Lung Cancer, Squamous · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#SmallCellLungCancer+3
Trials 5Status Active
AntibodyLimited DatastaleRocheApproved

atezolizumab (Tecentriq, Atezolizumab Injection [Tecentriq])

Hepatocellular Carcinoma · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Approved#monoclonal-antibody#HepatocellularCarcinoma+1
Trials 2Status Active
ADCLimited DatastaleThe Netherlands Cancer InstitutePhase 2

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

Non-Small Cell Lung Carcinoma; Advanced Non-Small Cell Squamous Lung Cancer · EGFR

#EGFR#ADC#Phase2#antibody-drug-conjugate#Non-SmallCellLungCarcinoma+2
Trials 1Status Recruiting
CGTLimited DatastaleBeijing Immunochina Medical Sci…Phase 2

AMT-116 CAR-T cells (AMT-116 CAR-T cells)

Melanoma; Non-small Cell Lung Cancer · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBeijing Immunochina Medical Sci…Phase 2

AMT-253 CAR-T cells (AMT-253 CAR-T cells)

Melanoma; Non-small Cell Lung Cancer · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleHenan Cancer HospitalPhase 2

durvalumab (Imfinzi, Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer)

SCLC, Extensive Stage · SCLC, Extensive Stage

#SCLCExtensiveStage#Antibody#Phase2#monoclonal-antibody#SCLC+2
Trials 1Status Active
AntibodyLimited DatastaleInstitut BergoniéPhase 2

durvalumab (Imfinzi, Association of lurbinectedin and durvalumab)

Small Cell Lung Cancer; Platinum-Sensitive Lung Small Cell Carcinoma · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Platinum-SensitiveLungSmallCellC+1
Trials 1Status Discontinued
CGTLimited DatastaleGuangzhou Anjie Biomedical Tech…Phase 2

CAR-T combining PD-1 Knockout (CAR-T combining PD-1 Knockout)

Lung Neoplasm Malignant; Non-small Cell Lung Cancer · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleHunan Province Tumor HospitalPhase 2

IBI-323 combined with bevacizumab plus Platinum (IBI-323 combined with bevacizumab plus Platinum)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Hunan
Trials 1Status Active

1 / 2 pages

← PreviousNext →